QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
NASDAQ:MTEM

Molecular Templates (MTEM) Stock Forecast, Price & News

$0.50
+0.02 (+4.17%)
(As of 06/7/2023 ET)
Compare
Today's Range
$0.45
$0.50
50-Day Range
$0.33
$0.49
52-Week Range
$0.31
$1.23
Volume
141,762 shs
Average Volume
506,366 shs
Market Capitalization
$28.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.00

Molecular Templates MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
100.0% Upside
$1.00 Price Target
Short Interest
Healthy
2.30% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.93
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.66) to ($0.30) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.73 out of 5 stars

Medical Sector

53rd out of 981 stocks

Pharmaceutical Preparations Industry

19th out of 464 stocks


MTEM stock logo

About Molecular Templates (NASDAQ:MTEM) Stock

Molecular Templates, Inc. engages in the discovery, development, and commercialization of biologic therapeutics for the treatment of cancers and other serious diseases. It utilizes its proprietary biologic drug platform to design and generate engineered toxin bodies, or ETBs. The company was founded by Eric E. Poma, Jean Gariépy, and Leigh Revers in 2000 and is headquartered in Austin, TX.

Receive MTEM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Molecular Templates and its competitors with MarketBeat's FREE daily newsletter.

MTEM Stock News Headlines

Sell Every Stock, Except ONE (Ticker Revealed)
We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.
Molecular Templates, Inc. (NASDAQ:MTEM) Short Interest Update
Sell Every Stock, Except ONE (Ticker Revealed)
We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.
Why Is Molecular Templates (MTEM) Stock Up 36% Today?
See More Headlines

MTEM Price History

MTEM Company Calendar

Last Earnings
3/30/2023
Today
6/07/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:MTEM
CUSIP
88580720
Employees
261
Year Founded
2009

Price Target and Rating

Average Stock Price Forecast
$1.00
High Stock Price Forecast
$1.00
Low Stock Price Forecast
$1.00
Forecasted Upside/Downside
+117.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-92,720,000.00
Net Margins
-126.49%
Pretax Margin
-125.71%

Debt

Sales & Book Value

Annual Sales
$19.75 million
Book Value
($0.27) per share

Miscellaneous

Free Float
40,348,000
Market Cap
$25.92 million
Optionable
Not Optionable
Beta
1.39

Social Links


Key Executives

  • Eric E. Poma
    Chief Executive & Scientific Officer, Director
  • Jason S. KimJason S. Kim
    President, COO, CFO & Treasurer
  • Roger J. Waltzman
    Chief Medical Officer
  • Michael Dowd
    Senior VP-Project & Alliance Management
  • Megan Filoon
    General Counsel













MTEM Stock - Frequently Asked Questions

Should I buy or sell Molecular Templates stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Molecular Templates in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" MTEM shares.
View MTEM analyst ratings
or view top-rated stocks.

What is Molecular Templates' stock price forecast for 2023?

1 brokerages have issued 1 year target prices for Molecular Templates' stock. Their MTEM share price forecasts range from $1.00 to $1.00. On average, they anticipate the company's share price to reach $1.00 in the next twelve months. This suggests a possible upside of 117.4% from the stock's current price.
View analysts price targets for MTEM
or view top-rated stocks among Wall Street analysts.

How have MTEM shares performed in 2023?

Molecular Templates' stock was trading at $0.3280 at the beginning of 2023. Since then, MTEM stock has increased by 40.2% and is now trading at $0.46.
View the best growth stocks for 2023 here
.

Are investors shorting Molecular Templates?

Molecular Templates saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 1,040,000 shares, a decrease of 14.8% from the April 30th total of 1,220,000 shares. Based on an average daily volume of 745,400 shares, the short-interest ratio is currently 1.4 days. Approximately 2.3% of the company's stock are short sold.
View Molecular Templates' Short Interest
.

When is Molecular Templates' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our MTEM earnings forecast
.

How were Molecular Templates' earnings last quarter?

Molecular Templates, Inc. (NASDAQ:MTEM) announced its quarterly earnings results on Thursday, March, 30th. The biotechnology company reported ($0.39) EPS for the quarter, missing analysts' consensus estimates of ($0.25) by $0.14. The biotechnology company had revenue of $2.61 million for the quarter, compared to the consensus estimate of $7.25 million. Molecular Templates had a negative trailing twelve-month return on equity of 1,843.37% and a negative net margin of 126.49%.

When did Molecular Templates' stock split?

Shares of Molecular Templates reverse split before market open on Wednesday, August 2nd 2017. The 1-11 reverse split was announced on Tuesday, August 1st 2017. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, August 1st 2017. An investor that had 100 shares of stock prior to the reverse split would have 9 shares after the split.

What other stocks do shareholders of Molecular Templates own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Molecular Templates investors own include ZIOPHARM Oncology (ZIOP), Novavax (NVAX), Gilead Sciences (GILD), TG Therapeutics (TGTX), CEL-SCI (CVM), Pfizer (PFE), Synergy Pharmaceuticals (SGYP), Amarin (AMRN), Corbus Pharmaceuticals (CRBP) and Exelixis (EXEL).

What is Molecular Templates' stock symbol?

Molecular Templates trades on the NASDAQ under the ticker symbol "MTEM."

Who are Molecular Templates' major shareholders?

Molecular Templates' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (1.33%), Renaissance Technologies LLC (0.45%), Carlyle Group Inc. (0.35%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Jason S Kim, Kevin M Lalande, Longitude Capital Partners Iii, Sean Mclennan, Shv Management Services, Llc and Target N V Biotech.
View institutional ownership trends
.

How do I buy shares of Molecular Templates?

Shares of MTEM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Molecular Templates' stock price today?

One share of MTEM stock can currently be purchased for approximately $0.46.

How much money does Molecular Templates make?

Molecular Templates (NASDAQ:MTEM) has a market capitalization of $25.92 million and generates $19.75 million in revenue each year. The biotechnology company earns $-92,720,000.00 in net income (profit) each year or ($1.08) on an earnings per share basis.

How many employees does Molecular Templates have?

The company employs 261 workers across the globe.

How can I contact Molecular Templates?

Molecular Templates' mailing address is 9301 AMBERGLEN BLVD. SUITE 100, AUSTIN TX, 78729. The official website for the company is www.mtem.com. The biotechnology company can be reached via phone at (512) 869-1555, via email at adam.cutler@mtem.com, or via fax at 650-474-2529.

This page (NASDAQ:MTEM) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -